Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Silo Pharma announced it has regained compliance with Nasdaq's minimum bid price rule, allowing continued trading on the Nasdaq Capital Market. The company is advancing its lead drug SPC-15 for PTSD towards a first-in-human clinical trial and developing its AI agents platform, QwikAgents. Silo Pharma focuses on novel therapeutics for stress-induced…